prmt5 inhibitor bms-986504
prmt5 inhibitor bms-986504: 8 clinical trials tracked.
prmt5 inhibitor bms-986504 evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
What is verified about prmt5 inhibitor bms-986504, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (8)
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
Primary endpoint: Part 1: Number of participants who achieve Objective Response (OR)
SynthEtic LEthal Cancer Therapy in Mesothelioma (SELECTmeso): a Molecularly Stratified Multi-arm Phase II Platform Trial for Patients With Relapsed Malignant Mesothelioma Candidate Specific Trial: SELECTmeso1 A Phase II Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
Primary endpoint: SELECTmeso Platform : Molecular profiling of participant's tumour block SELECTmeso1: Disease Control Rate (DCR) using RECIST 1.1 at 12 weeks.
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
Primary endpoint: Safety and adverse events (AEs)
A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors
Primary endpoint: determine a recommended phase II dose (RP2D) of BMS-986504 in combination with standard-of-care therapy
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Primary endpoint: Progression-free survival (PFS) by RECIST v1.1
A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of Navlimetostat (BMS-986504) in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion
Primary endpoint: Maximum Plasma Concentration (Cmax) of BMS-986504
A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of Navlimetostat (BMS-986504) Monotherapy and in Combination With Izalontamab Brengitecan in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss After Progression on Prior Therapies
Primary endpoint: Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]-BMS-986504 (MRTX1719) in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Primary endpoint: Maximum observed concentration (Cmax)